Efficacy and safety of leuprorelin acetate depot for prostate cancer

Urologia Internationalis

Volumn 56, Issue , 1996, Pages 23-30

  Kienle, E ^a   Lubben G ^a  

^a Takeda Pharma GmbH   (Germany)

Author keywords

Advanced prostatic carcinoma; Androgen deprivation; Leuprorelin acetate depot

Indexed keywords

ANDROSTANOLONE; FOLLITROPIN; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; FOLLITROPIN BLOOD LEVEL; HEADACHE; HOT FLUSH; HUMAN; INJECTION PAIN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; SUSTAINED RELEASE PREPARATION; SWEATING; TESTOSTERONE BLOOD LEVEL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; FOLLOW-UP STUDIES; HUMANS; LEUPROLIDE; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVIVAL RATE; TESTOSTERONE; TIME FACTORS;

EID: 0029876061     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000282865     Document Type: Article

References (16)

1. Huggins C, Hodges CV: Studies on prostatic cancer. II. The effect of castration, estrogen and androgen injections on scrum. Cancer Res 1944:1:293-297.
2. Bailar JC III, Byar DP: Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbcstrol and placebo. Cancer 1970;26:257-261.
3. Garnick MB, The Leuprolide Study Group: Leuprolide versus diethylstilbcstrol for metastatic prostate cancer. N Engl J Med 1984:311: 1281-1286.
4. Johnson E, Seely J, White W, De Sombre E: Endocrine-dependent rat mammary' tumor regression: Use of gonadotropin-releasing hormone analog. Science 1976:194:329-330.
5. O’Brien A, Grainger R, Butler MR: Experience with leuprorelin acetate as a depot formulation for prostate cancer in a long-term follow-up study; in Jakse G, Wolff J (eds): Endokrine Therapie des fortgeschrittencn Prostatakarzi-noms. Berlin. Springer. 1992, pp 73-89.
6. Fornara P: Multicentcr-Studie mit Enantone® Monats-Depot - Langzeitverlaufskontrolle; in Jakse G, Wolff J (eds): Endokrine Therapie des fortgeschrittenen Prostatakarzinoms. Berlin. Springer, 1992. pp 91-99.
7. Cirkcl U, et al: Experience with leuprorelin acetate depot in the treatment of fibroids: A German multicentre study. Int J Drug Ther 1992: 14(suppl A):37-50.
8. Gerhard I, et al: Treatment of endometriosis with leuprorelin acetate depot: A German multicentre study. Int J Drug Ther 1992; 14(suppl A):3-16.
9. Smith JA Jr: Androgen suppression by a gonadotropin-releasing hormone analogue in patients with metastatic carcinoma of the prostate. J Urol 1984;131:1110-1112.
10. Soloway MS: Zoladex versus orchiectomy in the treatment of advanced prostate cancer: A randomized trial. Urology 1991:37:46-51.
11. Peeling WB: Phase III studies to compare go-serelin (Zoladex) with orchiectomy and with dicthy 1stilbcstrol in treatment of prostatic carcinoma. Urology 1989;33(suppl 5):45-52.
12. Sharifi R, Lee M. Ojeda L. Ray P. Stobnicki M, Guinan P: Comparison of leuprolidc and di-cthylstilbestrol for stage D2 adenocarcinoma of prostate. Urology 1985:26:117-124.
13. Ogawa Y: Monthly microcapsule-depot form of LHRH agonist, Icuprorclin acetate (Enantonc® Depot): Formulation and pharmacokinetics in animals. Eur J Hosp Pharm 1992;2:120-127.
14. Toguchi H: Formulation study of lcuproreliti acetate to improve clinical performance. Int J Drug Ther 1992; 14(suppl A): 121-130.
15. International Union Against Cancer; in Jakse G, Wolff J (eds): TNM Classification of Malignant Tumours, ed 4. Berlin. Springer, 1987.
16. Dowsett M, et al: Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer. Int J Drug Ther 1992; 14(suppl A):97-103.